Sorafenib-Induced Hand-Foot Skin Reaction in a Patient With Acute Myeloid Leukemia Following Haploidentical Stem Cell Transplantation: A Case Report.
- 1Dermatology, Venereology and Leprosy, Sri Ramachandra Institute of Higher Education and Research, Chennai, IND.
Abstract
Sorafenib is an oral multikinase inhibitor approved for advanced hepatocellular carcinoma, renal cell carcinoma, and maintenance therapy in selected patients with FMS-like tyrosine kinase (FLT3)-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. We report the case of a 35-year-old woman with FLT3 internal tandem duplication (FLT3-ITD) and nucleophosmin 1 (NPM1)-positive acute myeloid leukemia (AML) who developed painful hyperkeratotic plantar plaques approximately eight weeks after initiating sorafenib therapy. Clinical examination revealed multiple symmetrical hyperkeratotic plaques involving the pressure-bearing areas of both soles, associated with pain and tenderness, resulting in significant impairment of daily activities. She was diagnosed with sorafenib-induced hand-foot skin reaction (HFSR) and was managed with topical keratolytic and corticosteroid therapy. This case highlights the importance of early recognition and prompt management of sorafenib-induced HFSRs to minimize morbidity and maintain oncological treatment.
Related
- Case Report: SAPHO syndrome mimicking osseous relapse after haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia
- TP53-mutated Therapy-related Leukemia with the Der(5;17)(p10;q10) Chromosomal Abnormality Following Chemotherapy for Acute Promyelocytic Leukemia Bridged to Allogeneic Hematopoietic Stem Cell Transplantation Using CPX-351
- Efficacy of Sorafenib Combined with Venetoclax and Azacitidine in Newly Diagnosed FLT3-ITD-Mutant Acute Myeloid Leukemia: Remission Efficacy and Prognostic Influence of Post-Remission Consolidation Therapy
- Extracellular vesicle phenotypic patterns associated with CMV, EBV and HHV-6 reactivation after haploidentical transplantation with post-transplant cyclophosphamide
- Haploidentical hematopoietic stem cell transplantation compared to immunosuppressive therapy plus eltrombopag as first-line treatment for severe aplastic anemia patients aged 40-65: a multicenter retrospective study.
BibTeX
@article{davis2026sorafenibinduced,
title = {{Sorafenib-Induced Hand-Foot Skin Reaction in a Patient With Acute Myeloid Leukemia Following Haploidentical Stem Cell Transplantation: A Case Report.}},
author = {Christa Davis and Arun Vignesh and Sudha Rangarajan and Murugan Sundaram and Adikrishnan Swaminathan},
journal = {Cureus},
year = {2026},
month = sep,
doi = {10.7759/cureus.116921},
url = {https://europepmc.org/article/MED/42928832},
note = {CC BY},
}
RIS
TY - JOUR
TI - Sorafenib-Induced Hand-Foot Skin Reaction in a Patient With Acute Myeloid Leukemia Following Haploidentical Stem Cell Transplantation: A Case Report.
AU - Christa Davis
AU - Arun Vignesh
AU - Sudha Rangarajan
AU - Murugan Sundaram
AU - Adikrishnan Swaminathan
PY - 2026
DA - 2026/09/25
JO - Cureus
DO - 10.7759/cureus.116921
UR - https://europepmc.org/article/MED/42928832
AB - Sorafenib is an oral multikinase inhibitor approved for advanced hepatocellular carcinoma, renal cell carcinoma, and maintenance therapy in selected patients with FMS-like tyrosine kinase (FLT3)-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. We report the case of a 35-year-old woman with FLT3 internal tandem duplication (FLT3-ITD) and nucleophosmin 1 (NPM1)-positive acute myeloid leukemia (AML) who developed painful hyperkeratotic plantar plaques approximately eight weeks after initiating sorafenib therapy. Clinical examination revealed multiple symmetrical hyperkeratotic plaques involving the pressure-bearing areas of both soles, associated with pain and tenderness, resulting in significant impairment of daily activities. She was diagnosed with sorafenib-induced hand-foot skin reaction (HFSR) and was managed with topical keratolytic and corticosteroid therapy. This case highlights the importance of early recognition and prompt management of sorafenib-induced HFSRs to minimize morbidity and maintain oncological treatment.
SN - 2168-8184
ER -